Syon Capital LLC Has $486,000 Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Syon Capital LLC lessened its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 41.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 36,680 shares of the company's stock after selling 25,626 shares during the quarter. Syon Capital LLC's holdings in Takeda Pharmaceutical were worth $486,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in TAK. QRG Capital Management Inc. increased its stake in shares of Takeda Pharmaceutical by 16.8% in the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock worth $4,364,000 after acquiring an additional 47,490 shares during the last quarter. Versant Capital Management Inc acquired a new stake in Takeda Pharmaceutical during the fourth quarter valued at $26,000. Russell Investments Group Ltd. boosted its position in Takeda Pharmaceutical by 48.6% during the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after purchasing an additional 14,831 shares during the last quarter. Franklin Resources Inc. acquired a new stake in Takeda Pharmaceutical during the third quarter valued at $244,000. Finally, US Bancorp DE boosted its position in Takeda Pharmaceutical by 21.2% during the fourth quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after purchasing an additional 21,744 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Up 0.9 %

Shares of NYSE:TAK traded up $0.14 on Monday, reaching $15.17. The company had a trading volume of 1,533,985 shares, compared to its average volume of 1,866,944. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $48.27 billion, a P/E ratio of 37.93, a P/E/G ratio of 0.24 and a beta of 0.39. The stock has a 50-day moving average price of $14.72 and a 200 day moving average price of $13.93.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.